BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 19669408)

  • 1. Loss of CSMD1 expression is associated with high tumour grade and poor survival in invasive ductal breast carcinoma.
    Kamal M; Shaaban AM; Zhang L; Walker C; Gray S; Thakker N; Toomes C; Speirs V; Bell SM
    Breast Cancer Res Treat; 2010 Jun; 121(3):555-63. PubMed ID: 19669408
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The expression pattern of MUC1 (EMA) is related to tumour characteristics and clinical outcome of invasive ductal breast carcinoma.
    van der Vegt B; de Roos MA; Peterse JL; Patriarca C; Hilkens J; de Bock GH; Wesseling J
    Histopathology; 2007 Sep; 51(3):322-35. PubMed ID: 17645748
    [TBL] [Abstract][Full Text] [Related]  

  • 3. p53 overexpression is a predictor of local recurrence after treatment for both in situ and invasive ductal carcinoma of the breast.
    de Roos MA; de Bock GH; de Vries J; van der Vegt B; Wesseling J
    J Surg Res; 2007 Jun; 140(1):109-14. PubMed ID: 17291532
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytoplasmic HuR expression is a prognostic factor in invasive ductal breast carcinoma.
    Heinonen M; Bono P; Narko K; Chang SH; Lundin J; Joensuu H; Furneaux H; Hla T; Haglund C; Ristimäki A
    Cancer Res; 2005 Mar; 65(6):2157-61. PubMed ID: 15781626
    [TBL] [Abstract][Full Text] [Related]  

  • 5. COX-2 expression in human breast carcinomas: correlation with clinicopathological features and prognostic molecular markers.
    Miglietta A; Toselli M; Ravarino N; Vencia W; Chiecchio A; Bozzo F; Motta M; Torchio B; Bocca C
    Expert Opin Ther Targets; 2010 Jul; 14(7):655-64. PubMed ID: 20536410
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Morphological and immunophenotypic analysis of breast carcinomas with basal and myoepithelial differentiation.
    Rakha EA; Putti TC; Abd El-Rehim DM; Paish C; Green AR; Powe DG; Lee AH; Robertson JF; Ellis IO
    J Pathol; 2006 Mar; 208(4):495-506. PubMed ID: 16429394
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of cyclooxygenase-2 in breast carcinogenesis and its relation to HER-2/neu and p53 protein expression in invasive ductal carcinoma.
    Cho MH; Yoon JH; Jaegal YJ; Choi YD; Lee JS; Lee JH; Nam JH; Choi C; Lee MC; Park CS; Woo Juhng S; Min KW
    Breast; 2006 Jun; 15(3):390-8. PubMed ID: 16169726
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of E2F-4 in invasive breast carcinomas is associated with poor prognosis.
    Rakha EA; Pinder SE; Paish EC; Robertson JF; Ellis IO
    J Pathol; 2004 Jul; 203(3):754-61. PubMed ID: 15221934
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overexpression of Cripto and its prognostic significance in breast cancer: a study with long-term survival.
    Gong YP; Yarrow PM; Carmalt HL; Kwun SY; Kennedy CW; Lin BP; Xing PX; Gillett DJ
    Eur J Surg Oncol; 2007 May; 33(4):438-43. PubMed ID: 17125961
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Survival analysis between patients with invasive ductal and invasive lobular breast cancer.
    Dian D; Herold H; Mylonas I; Scholz C; Janni W; Sommer H; Friese K
    Arch Gynecol Obstet; 2009 Jan; 279(1):23-8. PubMed ID: 18449551
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correlation of cyclooxygenase-2 and aromatase immunohistochemical expression in invasive ductal carcinoma, ductal carcinoma in situ, and adjacent normal epithelium.
    Oliveira VM; Piato S; Silva MA
    Breast Cancer Res Treat; 2006 Feb; 95(3):235-41. PubMed ID: 16322898
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Podoplanin expression by cancer-associated fibroblasts predicts poor outcome in invasive ductal breast carcinoma.
    Pula B; Jethon A; Piotrowska A; Gomulkiewicz A; Owczarek T; Calik J; Wojnar A; Witkiewicz W; Rys J; Ugorski M; Dziegiel P; Podhorska-Okolow M
    Histopathology; 2011 Dec; 59(6):1249-60. PubMed ID: 22175904
    [TBL] [Abstract][Full Text] [Related]  

  • 13. E-cadherin expression in invasive non-lobular carcinoma of the breast and its prognostic significance.
    Rakha EA; Abd El Rehim D; Pinder SE; Lewis SA; Ellis IO
    Histopathology; 2005 Jun; 46(6):685-93. PubMed ID: 15910600
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of cytokeratin markers, ER-alpha, PR, HER-2/neu, and EGFR in pure ductal carcinoma in situ (DCIS) and DCIS with co-existing invasive ductal carcinoma (IDC) of the breast.
    Steinman S; Wang J; Bourne P; Yang Q; Tang P
    Ann Clin Lab Sci; 2007; 37(2):127-34. PubMed ID: 17522367
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression and possible prognostic role of MAGE-A4, NY-ESO-1, and HER-2 antigens in women with relapsing invasive ductal breast cancer: retrospective immunohistochemical study.
    Bandić D; Juretić A; Sarcević B; Separović V; Kujundzić-Tiljak M; Hudolin T; Spagnoli GC; Cović D; Samija M
    Croat Med J; 2006 Feb; 47(1):32-41. PubMed ID: 16489695
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hypoxia-inducible factor 1alpha is closely linked to an aggressive phenotype in breast cancer.
    Yamamoto Y; Ibusuki M; Okumura Y; Kawasoe T; Kai K; Iyama K; Iwase H
    Breast Cancer Res Treat; 2008 Aug; 110(3):465-75. PubMed ID: 17805961
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhanced prediction of breast cancer prognosis by evaluating expression of p53 and prostate-specific antigen in combination.
    Yu H; Levesque MA; Clark GM; Diamandis EP
    Br J Cancer; 1999 Oct; 81(3):490-5. PubMed ID: 10507775
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The extracellular matrix protein ITIH5 is a novel prognostic marker in invasive node-negative breast cancer and its aberrant expression is caused by promoter hypermethylation.
    Veeck J; Chorovicer M; Naami A; Breuer E; Zafrakas M; Bektas N; Dürst M; Kristiansen G; Wild PJ; Hartmann A; Knuechel R; Dahl E
    Oncogene; 2008 Jan; 27(6):865-76. PubMed ID: 17653090
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of c-erbB2, cyclin D1 and estrogen receptor and their clinical implications in the invasive ductal carcinoma of the breast.
    Lee A; Park WC; Yim HW; Lee MA; Park G; Lee KY
    Jpn J Clin Oncol; 2007 Sep; 37(9):708-14. PubMed ID: 17940078
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Coexistence of HER2 over-expression and p53 protein accumulation is a strong prognostic molecular marker in breast cancer.
    Yamashita H; Nishio M; Toyama T; Sugiura H; Zhang Z; Kobayashi S; Iwase H
    Breast Cancer Res; 2004; 6(1):R24-30. PubMed ID: 14680497
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.